Weigh Risks And Benefits Of Old And New Oral Anticoagulants

NPS MedicineWise is urging health professionals to weigh the risks and benefits of oral anticoagulant therapies in people with non-valvular atrial fibulation (AF) following the Pharmaceutical Benefits Advisory Committee (PBAC) recommendation that newer oral anticoagulants (NOACs) be listed on the Pharmaceutical Benefits Scheme (PBS). Following an extensive review of NOACs over the past two years, PBAC has now recommended that dabigatran (Praxada), rivaroxaban (Xarelto), and apixaban (Eliquis) be subsidised under the scheme for stroke prevention in non-valvular AF... via Health News from Medical News Today Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/05/weigh-risks-and-benefits-of-old-and-new.html